Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00094107
Status:
COMPLETED
Last Update Posted:
2012-06-26
First Post:
2004-10-11
Brief Title:
Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Sponsor:
Pfizer
Organization:
Pfizer
Study Overview
Official Title:
Phase 2 Study Of The Anti-Angiogenesis Agent AG-013736 In Patients With Metastatic Melanoma
Status:
COMPLETED
Status Verified Date:
2012-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a Phase 2 study being conducted at multiple centers in the United States and France Patients having melanoma that has spread to other parts of the body ie metastatic are eligible to participate Patients must have disease that has been treated with no more than 1 prior treatment for metastatic disease prior adjuvant treatment for localized disease does not count as prior treatment for metastatic disease The purpose of the study is to test whether the angiogenesis inhibitor AG-013736 is an effective treatment for metastatic melanoma as shown by the number of patients in the study who experience significant and durable tumor shrinkage
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None